File(s) under embargo

Reason: 12 month publisher embargo

5

month(s)

30

day(s)

until file(s) become available

Lower Risk of Hospitalisation for Heart Failure, Kidney Disease and Death with Sodium Glucose Co-Transporter-2 Compared to Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Regardless of Prior Cardiovascular or Kidney Disease: A Retrospective Cohort Study in UK Primary Care.

journal contribution
posted on 09.06.2021, 10:37 by Iskandar Idris, Ruiqi Zhang, Jil Billy Mamza, Mike Ford, Tamsin Morris, Amitava Banerjee, Kamlesh Khunti, Jonathan Tulip Mark Greener
Background
Sodium–glucose cotransporter–2 inhibitors (SGLT2i) reduce the risk of cardiovascular and, or renal disease (CVRD). Dipeptidyl peptidase–4 inhibitors (DPP4i) have not shown these effects.

Methods
This retrospective cohort study propensity matched 24,438 patients receiving a SGLT2i 1:1 to a person receiving a DDP4i, stratified based on presence of CVRD. Primary outcomes were the time to each of the following: all–cause mortality, cardiovascular death or hospitalisation for heart failure (HF), myocardial infarction, stroke and chronic kidney disease (CKD).

Findings
Overall, SGLT2i were associated with reductions in all–cause mortality, cardiovascular mortality , HF hospitalisation and CKD hospitalisation compared with DPP4i. In patients with no CVRD history, SGLT2i were associated with reductions in all–cause mortality (0·71, 0·57–0·88; p=0·002), HF hospitalisation (0·76, 0·59–0·98; p=0·035) and CKD hospitalisation (0·75, 0·63–0·88; p<0·001). In patients with established cardiovascular disease (CVD) or at high risk, SGLT2i were associated with reductions in all–cause mortality (0·69, 0·59–0·82); p<0·001), cardiovascular mortality (0·76, 0·62–0·95; p=0·014), HF hospitalisation (0·73, 0·63–0·85; p<0·001), stroke hospitalisation (0·75, 0·59–0·94, p=0·013) and CKD hospitalisation (0·49, 0·43–0·54, p<0·001). Results were consistent across subgroups and sensitivity analyses.

Interpretation
SGLT2i were associated with reduced risk of all–cause mortality and hospitalisation for HF and CKD compared with DPP4–i, highlighting the need to introduce SGLT2i early in the management of T2D patients.

History

Author affiliation

Diabetes Research Centre, College of Life Sciences

Version

AM (Accepted Manuscript)

Published in

Diabetes, Obesity and Metabolism

Publisher

Wiley

issn

1462-8902

eissn

1463-1326

Acceptance date

26/04/2021

Copyright date

2021

Available date

26/04/2022

Spatial coverage

England

Language

eng

Usage metrics

Categories

Exports